4 recruiting, 3 completed, 3 unknown, 1 not yet recruiting. 5 Phase 3, 2 Not applicable, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Recruiting 1, Terminated 1, Unknown 1 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 2 | Not yet recruiting 1, Unknown 1 |
Follow CIN3: new trials by email Literature Review of CIN3 trials Research Report on CIN3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya 5% 5-fluorouracil Topical Cream, Placebo Cream - HIV Infections, HPV Infection | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 140 | 2026-09-01 | 2026-08-27 |
| Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa Urine HPV testing, Self-collected cervicovaginal specimen, Provider-collected cervical samples - Cervical Cancer, CIN2 | Not applicable | Recruiting | UNC Lineberger Comprehensive Cancer Center | 300 | 2023-05-11 | 2026-09-30 |
| Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV 5 Fluorouracil (5 FU) Cream, Placebo - Cervical Cancer, CIN2 | Not applicable | Completed | UNC Lineberger Comprehensive Cancer Center | 180 | 2023-03-22 | 2026-08-21 |
| A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha), Placebo - Cervical Cancer, Genital Wart | Phase 3 | Terminated | Shanghai Bovax Biotechnology Co., Ltd. | 3131 | 2022-12-09 | 2023-07-21 |
| Regression of Cervical Precancerous Lesions and Associated Risk Factors Colposcopy - Cervix Uteri SIL, HPV | Recruiting | General University Hospital, Prague | 300 | 2022-09-01 | 2026-02-25 | |
| Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine HPV Infections, Cervical Cancer Stage IIa | Recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 600 | 2022-05-14 | 2024-04-17 | |
| Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years 2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years - HPV Infections, Cervical Cancer Stage IIa | Phase 3 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 1348 | 2021-09-15 | 2024-04-17 |
| Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II Vvax001 therapeutic cancer vaccine - CIN3, Cervical Intraepithelial Neoplasia | Phase 2 | Unknown | University Medical Center Groningen | 18 | 2021-03-23 | 2023-08-29 |
| Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9 - HPV Infections, Cervical Cancer | Phase 3 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 1200 | 2020-09-19 | 2023-11-24 |
| Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL® - Cervical Cancer, Vulvar Cancer | Phase 3 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 1680 | 2020-05-28 | 2022-02-25 |
| Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL® - Cervical Cancer, Vulvar Cancer | Phase 3 | Recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 8000 | 2020-04-28 | 2024-06-07 |
| Cervical Cancer Screening With Human Papillomavirus Testing HPV screening - CIN3, CIN2 | Unknown | International Agency for Research on Cancer | 50000 | 2013-05-01 | 2023-03-14 |
Uterine Cervical Neoplasms (10) · Condylomata Acuminata (6) · Vaginal Neoplasms (5) · Papillomavirus Infections (4) · Vulvar Neoplasms (3) · Uterine Cervical Dysplasia (2) · Acquired Immunodeficiency Syndrome (1) · HIV Infections (1)
Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Genital Diseases (11) · Genital Diseases, Female (11) · Neoplasms (11) · Urogenital Diseases (11) · Uterine Cervical Diseases (11) · Uterine Diseases (11) · Genital Neoplasms, Female (10) · Neoplasms by Site (10) · Urogenital Neoplasms (10) · Uterine Neoplasms (10) · Communicable Diseases (8) · Infections (8) · Sexually Transmitted Diseases (8)
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (2) · Vaccines, Synthetic (2) · Colposcopy (1) · Fluorouracil (1)
Shanghai Bovax Biotechnology Co., Ltd. (6) · UNC Lineberger Comprehensive Cancer Center (3) · General University Hospital, Prague (1) · International Agency for Research on Cancer (1) · University Medical Center Groningen (1)
China (6) · South Africa (2) · Argentina (1) · Bolivia (1) · Colombia (1) · Costa Rica (1) · Czechia (1) · Honduras (1) · Kenya (1) · Mexico (1) · Netherlands (1) · Paraguay (1) · Peru (1) · Uruguay (1)
Carla Chibwesha, MD, MSc (2) · Chemtai Mungo, MD, MPH (1) · Jikai Zhang (1) · Rolando Herrero, MD, PhD (1) · Ting Huang (1)
PMID 29944728, PMID 32448795, PMID 36451311, PMID 40215795, PMID 40435891, PMID 40832398, PMID 41044173, PMID 41780745, PMID 41890998, PMID 41891028
R01CA250850 (1), R37CA306827 (1), U54CA254564 (1)